Cord Blood News Volume 7.41 | Oct 22 2015

Ectopic Bone Formation by Mesenchymal Stem Cells Derived from Human Term Placenta and the Decidua
Investigators provide evidence to support chorionic-derived mesenchymal stem cells (MSCs) and decidua-derived MSCs as cellular candidates with potent bone forming capacity. [PLoS One] Full Article

Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model
The effects of accessory cells, particularly natural killer cells, on human cord blood hematopoietic stem cell functions were assessed in vitro and in vivo. [PLoS One] Full Article

A Novel Bioreactor and Culture Method Drives High Yields of Platelets from Stem Cells
CD34 cells isolated from umbilical cord blood were expanded with a variety of reagents and on a nanofiber membrane using serum-free medium. A novel bioreactor was developed that recapitulated aspects of the marrow vascular niche. [Transfusion] Abstract

Double Umbilical Cord Blood Transplantation Is Effective Therapy for Relapsed or Refractory Hodgkin Lymphoma
Researchers analyzed 27 consecutive, heavily pre-treated patients receiving double umbilical cord blood transplantation for relapsed/refractory Hodgkin lymphoma. [Leuk Lymphoma] Abstract

Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke
Scientists previously demonstrated enhanced functional effects of co-treatment with granulocyte-colony stimulating factor and human umbilical cord blood cell transplantation in animal models of traumatic brain injury. Here, they suggest that the aforementioned combination therapy may also produce synergistic effects in stroke. [Transl Stroke Res] Abstract

Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH
The authors report a novel reduced intensity conditioning regimen of alemtuzumab, 4 Gy total body irradiation and fludarabine for salvage of primary graft failure followed by double umbilical cord blood transplant. [Pediatr Blood Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Kiadis Pharma Announces Enrollment of First Patient in Its Repeat-Dosing Phase II Clinical Trial with ATIR101™
Kiadis Pharma N.V. announced that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its lead product ATIR101™. [Kiadis Pharma N.V.] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Leukemia Stem Cell Biology (Lund University)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Fellow – Computational Biology/Bioinformatics (Princess Margaret Cancer Center)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.